Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
批准号:
8706961
负责人:
CRAIG LINDSLEY
金额:
$39.23万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-05-20 至 2018-05-31
关键词:
AddressAdverse effectsAgonistAntipsychotic AgentsArrestinsBehavioralBiological AssayBrainCellsCentral Nervous System DiseasesChemicalsClinicalClinical ResearchCognitiveComplexCoupledCouplingDataDevelopmentDrug KineticsEnsureFunctional disorderFundingGenetic ModelsGlutamatesGoalsGrantHealthHippocampus (Brain)HumanImpaired cognitionIn VitroKetamineLeadLigandsMAPK3 geneMediatingMental disordersMissionModelingMolecular GeneticsMusMuscarinic Acetylcholine ReceptorMuscarinic M1 ReceptorN-Methyl-D-Aspartate ReceptorsN-MethylaspartateNR1 geneNational Institute of Mental HealthNeurobehavioral ManifestationsPathway interactionsPerformancePharmaceutical ChemistryPharmaceutical PreparationsPharmacologyPhysiologicalPropertyRattusResearchRodentRodent ModelRoleSchizophreniaSeriesSignal TransductionSiteSliceSpecificitySymptomsSystemTestingTherapeuticTherapeutic AgentsTimebasecholinergicclinical effectcognitive functionfunctional disabilityhigh throughput screeningimprovedin vivonovelnovel therapeuticspatch clamppostsynapticpre-clinicalpublic health relevancerelease of sequestered calcium ion into cytoplasmresearch studysmall moleculetransmission process
中文摘要
描述(申请人提供):目前的抗精神病药物治疗可以解决阳性症状,但阴性和认知症状仍然管理不善,如果有的话,并且是功能性残疾的关键预测因素。大量的解剖学、分子、遗传学、临床前行为学和人类临床研究表明,能够增强胆碱能传递或激活M受体(mAChRs,M1-M5)的药物,特别是M1,在治疗精神分裂症的阳性、阴性和认知症状以及其他中枢神经系统疾病的认知功能障碍方面具有令人兴奋的治疗潜力。然而,以前开发的选择性激活M1受体的化合物在临床开发中失败了,原因是M1缺乏真正的特异性,以及与激活其他mAChR亚型(M2-M5)相关的不良反应。此外,由于缺乏高度选择性的化合物,因此无法确定这些化合物的行为和临床效应是否由M1介导。从机制上讲,耐人寻味的是,选择性M1激活很好地符合精神分裂症的谷氨酸假说或NMDA(N-甲基-D-天冬氨酸)功能低下假说,因为M1和NR1a NMDA亚单位都共同定位于特定的突触后位置,并由正位mAChR激动剂激活M1,以及最近在上一资助期间开发的高选择性M1变构激动剂和M1正变构调节剂(PAM),它们增强了海马片上的NMDA电流,在临床前抗精神病啮齿动物模型中显示出强大的疗效,并在多个海马区驱动的模型中改善认知表现。当这笔赠款最初在四年前获得资助时,还没有真正具有选择性的M1激动剂,具有必要的mAChR选择性、辅助药理学或DMPK特性来研究体内选择性M1激活的作用。因此,在之前的资助期间,我们非常成功地开发了大量高度选择性的M1激动剂(包括功能上的M1选择性激动剂和代表多种化学类型的M1 PAM),具有前所未有的清洁辅助药理和DMPK图谱,使体内研究能够通过从功能M1高通量筛选中命中的化学优化来执行。基于配体偏向的信号现象,为了在精神分裂症的NMDA功能低下模型的背景下明确评估选择性M1激活,我们必须开发一套具有类似DMPK特性的M1配体,激活所有M1介导的通路,以及体内选择的特定通路。这项研究与NIMH的使命直接相关,并有可能直接影响人类健康。我们这个项目的目标是同时开发选择性的M1变构激动剂和M1阳性变构调节剂,这些药物具有可接受的临床前和最终临床开发曲线,可能导致一种治疗精神分裂症阳性、阴性和认知症状的新药。
英文摘要
DESCRIPTION (provided by applicant): Current antipsychotic therapies can address the positive symptoms, but the negative and cognitive symptoms remain poorly managed, if at all, and are key predictors of functional disability. A large number of anatomical, molecular, genetic, preclinical behavioral and human clinical studies have provided strong evidence that agents able to enhance cholinergic transmission or activate muscarinic acetylcholine receptors (mAChRs, M1- M5), notably M1, have exciting therapeutic potential for the treatment of the positive, negative and cognitive symptoms of schizophrenia as well as cognitive dysfunction in other CNS disorders. However, previous compounds developed to selectively activate M1 receptors have failed in clinical development due to a lack of true specificity for M1 and adverse effects associated with activation of other mAChR subtypes (M2-M5). Furthermore, the lack of highly selective compounds has made it impossible to definitively determine whether the behavioral and clinical effects of these compounds are mediated by M1. Mechanistically, it is intriguing that selective M1 activation fits well with the glutamate hypothesis, or NMDA (N-methyl-D-aspartate) hypofunction hypothesis of schizophrenia, as both M1 and the NR1a NMDA subunit are co-localized at specific postsynaptic sites, and activation of M1 by orthosteric mAChR agonists, and more recently, highly selective M1 allosteric agonists and M1 positive allosteric modulators (PAMs), developed during the previous funding period, potentiate NMDA currents in hippocampal slices, display robust efficacy in preclinical antipsychotic rodent models and improve cognitive performance in multiple hippocampal-driven models. When this grant was initially funded four years ago, no truly selective M1 activators existed with the requisite mAChR selectivity, ancillary pharmacology or DMPK properties to study the role of selective M1 activation in vivo. Thus, during the previous funding period, we were highly successful in developing a vast array of highly selective M1 activators (both functionally M1 selective agonists and M1 PAMs representing multiple chemotypes) with unprecedented, clean ancillary pharmacology and DMPK profiles enabling in vivo studies to be performed via the chemical optimization of hits from a functional M1 high-throughput screen. Based on ligand-biased signaling phenomena, in order to definitively evaluate selective M1 activation in the context of NMDA hypofunction models of schizophrenia, we must develop a suite of M1 ligands with comparable DMPK properties that activate all M1-mediated pathways, as well as select, specific pathways in vivo. This research has direct relevance to the mission of NIMH and has the potential to impact human health directly. Our goal for this project is to develop, in parallel, selective M1 allosteric agonists and M1 positive allosteric modulators with acceptable profiles for preclinical and ultimately clinical development that may lead to a new drug for the treatment of the positive, negative and cognitive symptoms of schizophrenia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders
-
批准号:10426338
-
项目类别:
-
资助金额:$69.49万
-
财政年份:2020
-
负责人:CRAIG LINDSLEY
-
依托单位:
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders
-
批准号:10674501
-
项目类别:
-
资助金额:$69.77万
-
财政年份:2020
-
负责人:CRAIG LINDSLEY
-
依托单位:
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders
-
批准号:10093390
-
项目类别:
-
资助金额:$74.11万
-
财政年份:2020
-
负责人:CRAIG LINDSLEY
-
依托单位:
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders
-
批准号:10266776
-
项目类别:
-
资助金额:$69.51万
-
财政年份:2020
-
负责人:CRAIG LINDSLEY
-
依托单位:
Allosteric modulators of the glucagon-like peptide-1 receptor
-
批准号:8996184
-
项目类别:
-
资助金额:$16.87万
-
财政年份:2014
-
负责人:CRAIG LINDSLEY
-
依托单位:
Center base project #2
-
批准号:8189624
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2010
-
负责人:CRAIG LINDSLEY
-
依托单位:
Medicinal Chemistry
-
批准号:7988517
-
项目类别:
-
资助金额:$63.5万
-
财政年份:2010
-
负责人:CRAIG LINDSLEY
-
依托单位:
Chemistry Core
-
批准号:8139981
-
项目类别:
-
资助金额:$331.86万
-
财政年份:2010
-
负责人:CRAIG LINDSLEY
-
依托单位:
Center base project #1
-
批准号:8189623
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2010
-
负责人:CRAIG LINDSLEY
-
依托单位:
Administrative Core
-
批准号:8139980
-
项目类别:
-
资助金额:$26.82万
-
财政年份:2010
-
负责人:CRAIG LINDSLEY
-
依托单位:
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction
-
批准号:7347914
-
项目类别:
-
资助金额:$42.83万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development
-
批准号:8139983
-
项目类别:
-
资助金额:$518.84万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
-
批准号:9250204
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
-
批准号:7625071
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction
-
批准号:8071079
-
项目类别:
-
资助金额:$39.86万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
-
批准号:8260205
-
项目类别:
-
资助金额:$34.19万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction
-
批准号:8262403
-
项目类别:
-
资助金额:$39.44万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
-
批准号:8503224
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia
-
批准号:8068235
-
项目类别:
-
资助金额:$34.19万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development
-
批准号:8337390
-
项目类别:
-
资助金额:$300.0万
-
财政年份:2008
-
负责人:CRAIG LINDSLEY
-
依托单位:
海外基金